Cassava Sciences Inc SAVA:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/28/22 EST
40.20quote price arrow up+0.45 (+1.13%)
Volume
286,522
Close
39.75quote price arrow up+2.09 (+5.55%)
Volume
1,078,868
52 week range
17.15 - 146.16
Loading...
  • Open37.55
  • Day High39.96
  • Day Low36.51
  • Prev Close37.66
  • 52 Week High146.16
  • 52 Week High Date07/29/21
  • 52 Week Low17.15
  • 52 Week Low Date01/28/21

Key Stats

  • Market Cap1.591B
  • Shares Out40.02M
  • 10 Day Average Volume1.85M
  • Dividend-
  • Dividend Yield-
  • Beta0.63
  • YTD % Change-9.04

KEY STATS

  • Open37.55
  • Day High39.96
  • Day Low36.51
  • Prev Close37.66
  • 52 Week High146.16
  • 52 Week High Date07/29/21
  • 52 Week Low17.15
  • 52 Week Low Date01/28/21
  • Market Cap1.591B
  • Shares Out40.02M
  • 10 Day Average Volume1.85M
  • Dividend-
  • Dividend Yield-
  • Beta0.63
  • YTD % Change-9.04

RATIOS/PROFITABILITY

  • EPS (TTM)-0.55
  • P/E (TTM)-72.56
  • Fwd P/E (NTM)-17.79
  • EBITDA (TTM)-20.826M
  • ROE (TTM)-14.29%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date03/21/2022
  • Ex Div Date12/13/2010
  • Div Amount2.00
  • Split Date-
  • Split Factor-

Latest On Cassava Sciences Inc

There is no recent news for this security.

Profile

MORE
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimers disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimers brain. The SavaDx, is an early-stage program focused...
Remi Barbier
Chairman of the Board, President, Chief Executive Officer
Eric Schoen
Chief Financial Officer
Address
7801 N Capital of Texas Hwy Ste 260
Austin, TX
78731-1192
United States

Top Peers

SYMBOLLASTCHG%CHG
MORF
Morphic Holding Inc
40.95+2.69+7.03%
SANA
Sana Biotechnology Inc
8.06+0.11+1.38%
PTGX
Protagonist Therapeutics Inc
28.15+1.77+6.71%
CLDX
Celldex Therapeutics Inc
29.02+1.38+4.99%
ISEE
Iveric Bio Inc
13.19+0.84+6.80%